London-listed drugmaker Shire is considering a bid for New Jersey-based NPS Pharmaceuticals, FT Alphaville reported on Friday citing sources. Shire has been working with advisers and held internal discussions about a potential cash offer for NPS, a rare disease specialist, valuing the business at just over $4 billion, the Financial Times blog said.Shares in Nasdaq-listed NPS were trading 15.5 percent higher at 1500 GMT giving the company a market capitalisation of $2.92 billion. Shares in Shire were trading down 1.4 percent.(Reporting By Anjuli Davies, editing by Steve Slater)
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. Shares of NPSP traded higher by 23.48% or $6.446/share to $33.90. In the past year, the shares have traded as low as $14.06 and as high as $39.68. On average, 2091890 shares of NPSP exchange hands on a given day and today's volume is recorded at 5366522.
Source
